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Event Name: 2005 Molecular Imaging Radionuclide Therapy (MIRT) Workshop: Translational Applications of 
Molecular Imaging and Radionuclide Therapy 
Date Held: June 17 – 18, 2005  Attendance:  103 
Location: Intercontinental Toronto Centre Hotel (The Ballroom), Toronto, Canada 
 
This meeting was organized by the Society of Radiopharmaceutical Sciences (SRS)  and the Society of Nuclear 
Medicine Radiopharmaceutical Science Council (RPSC) and Molecular Imaging Task Force. The RPSC has 
joined with the SRS to present a series of lectures to educate pre-doctoral and post-doctoral radiopharmaceutical 
scientists in the design of molecular probes.  This meeting was supported by a Grant from the U.S. Department 
of Energy Office of Biological and Environmental Research.  
 
MIRT Organizers/Moderators: 
William C. Eckelman, PhD 
Michael J. Welch, PhD 
David R. Vera, PhD 
      
MIRT Educational Faculty Topic
Yu-Shin Ding, Brookhaven National Labs New generation of radiotracers 
 
Bernd Pichler, University of Tuebingen 
 
Labeling of stem cells 
 
David Vera, UC-San Diego 
 
A receptor-binding optical imaging agent for in vivo measurement 
of receptor biochemistry 
 
George Sgouros, Johns Hopkins Medical Institute 
 
Trends in dosimetry for therapy 
 
Richard Laforest, Washington University 
 
Comparing five methods for obtaining input functions 
 
Hank Kung, University of Pennsylvania 
 
Mass effects in SPECT, PET, and optical imaging 
 
Kathleen Schmidt, NIMH 
 
Resolution, sensitivity, and precision with autoradiography and 
small animal imaging 
 
Paul Scheibe 
 
What is to be gained by imaging the same animal before and after 
treatment? 
 
David Mankoff, University of Washington 
 
True tracers: Comparing FDG & glucose with FLT and thymidine 
 
Karen Kurdziel, Virginia Commonwealth 
University 
 
Imaging multi-drug resistance 
 
Kate Dadachova, Albert Einstein College of 
Medicine 
 
NaI symporter-expressing tissues in vivo 
 
Rob Mairs, University of Glasgow 
 
Gene manipulation to enhance targeted radionuclide therapy 
 
Jorge Carrasquillo, NIH Clinical Center 
 
Radiolabeled antibodies in the clinic: Individualized therapy 
 
Wynn Volkert, University of Missouri 
 
Radiolabeled peptides for diagnosis and therapy 
 
Ronald Blasberg, Memorial Sloan Kettering 
Cancer Center 
 
Reporter gene studies with nuclear and optial tracers: The impact 
of a diagnostic scan on therapy selection 
 
David Scheinberg 
 
 
Unique applications of alpha therapy 
 
